Get started
PFIZERPFIZERPFIZER

PFIZER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

1PFE trade ideas

Bullish Charts - Oversold & Undervalued Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreement with Merck KGaA; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and collaboration with Valneva SE to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer is one of the most unappreciated stocks in its industry and the low price shows. Recently, institutions have taken notice and started upgrading the stock with price targets north of $40.00 a share. Pfizer is also working on a COVID-19 vaccine and could be months ahead of other companies. On the daily chart, the stock is sitting is sitting and bouncing off support around $33.00. It's ready for a move up any day. Long!
NYSE:PFELong
by HotCharts
PFIZER SHORT Trading PlanEU states back spending up to $2.7 billion upfront on COVID-19 vaccines however,EU officials said the bloc would not buy vaccines produced exclusively in the United States, which includes PFIZER, fearing that would delay supplies to Europe. Hence, I expect the share price will dip further. Key Trading Plan: i) SHORT when it reaches the pull back price at 34.98 and it breaks support level at 32.87 before reaching target Take Profit point at 28.28. ii) LONG when the price breaks the resistance level of 36.89 with the target Take Profit point at 39.33 Author: S.I.D. Aizu
NYSE:PFEShort
by SIDCapital
Pfizer: PFE. Hardly any downside. Perfect Entry.The bad news with Pfizer's clinical trial is great news for traders and investors. Why? Because the 'bottom' has been gauged by this piece of over the weekend news. The bad news does not materially affect existing revenue stream and earnings. The lack of movement intraday suggests that institutions have completely priced in the negative effect of the news before market open. Anyone who wanted and NEEDED to sell has mostly sold, and there was no lack of buyers to take those orders at the $35.50. Perfect opportunity for a long trade, short term or long. Anything above 34.50 is a BUY. Interval Targets are the Fibonacci levels on the chart. Final target: $45
NYSE:PFELong
by yujingr
5 Stocks we are looking into for the Covid-19 VaccineFirst off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, let me get into my insights. There was rumors that AstraZeneca wanted to merge w/ Gilead. However, it looks like this may not happen. Until, the books are closed don't get your hopes up, but invest as if you expect something like this to go down. As far as stocks such as Pfizer, Pfizer so far is greatly underrated in terms of growth potential during the vaccine trials period, and likely because of that it is due for a bullish run quite soon. NVAX and Moderna, I believe already have the most stable growth potential given the logarithmic curves. These 5 stocks may be quite interesting to look at given all these giants from Pfizer to Moderna to Gilead are working on being the forefront of the expected Covid19 vaccine delivery. If this is a huge revenue booster, that means obvious profit turn over potential. Also, it is likely better for a buy entry previous to August, September, and the winter when hype may start increasing. Lots of the excitement have very recently slowed down, and you likely don't want to wait for the hype if you do long term holds.
NYSE:PFELong
by gamer456148
1
PFE Is A Value StockPfizer has maintained the same amount of revenues since 2010 which actually means it’s shrinking a bit (inflation) but this stock has a lot of value to offer. Their annual EPS is $2.80 and they pay out an annual dividend of $1.52 (4% yield) of which increases 16c every year. They have a healthy and steady Cash Flow of $4.20 and their shares outstanding have decreased at a 2-3% rate every year. Pfizer is a Pharmaceutical company that develops and markets medicine for humans and animals valued at 200Bn
NYSE:PFELong
by BlueFlamingo
PFE make ready for the long.Hello, What is PFE? Pfizer Canada is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. News June 2 (Reuters) - Pfizer Inc PFE.N said on Tuesday it will invest up to $500 million into publicly-traded drug developers to fund their treatment candidates and provide access to the U.S. drugmaker's scientific expertise. Educational Trade Positioning and Exits. My Trade Advice For You When I present a chart, that does not mean get in now. Getting in requires a set of rules and I will try to explain that in simple terms. A) What you need to do first is to understand the trend. Is it a bear or bull market? The direction is key by looking at the monthly, weekly, and daily time frame. You look for support and resistance within these timeframes and by understanding the trend, you can then decide if we are going to test these areas in a short or long position. Knowing the support/resistance areas, you can then assume that price will test these areas 1) Daily, 2) Weekly, 3) Monthly however you most know that the daily can affect the weekly or weekly affect the monthly and reverse. That is why you always look for the direction of the market first. B)Trendlines are drawn horizontally and diagonally by using a drawing tool to place on the tops of the candles for resistance and at the bottoms of the candles for support. This is how you find support and resistance on different timeframes. C) When getting into a position, this is where you need to have your rules in place. Entry into a short/long position is done on the 4-hour chart. Your tools will be the RSI and Fibonacci Retracement Tool. a) we now know the trend b) we know the probable areas of where the price is going, c) now we need to know when and where to get in D) Using our fib tool we are looking at the 4hr chart and will measure the previous impulse to find where this correction will occur. Here is an example but done on the monthly chart. We see that resistance was just above the golden ration (.618%) then we had a retest (rejection) near the golden ratio. On a 4hr chart, you would have seen the entry point and would have placed a stop at the golden ratio. Here is a look at the fact on a 4hr chart. We also use the RSI for further confluence for our entry position. Are we overbought or oversold? Overbought, you want to think about a Short and oversold, you want to think about a Long. Using the RSI and the Fib tool with the foreknowledge of the trend we are better equipped for making an entry. Here is an example of the RSI along with the fib tool. Summary 1) we know the trend direction, 2) We know support or resistance for where we will want to enter a position, 3) we used our Fib Tool and the RSI to help us make a decision for entry 4) we waited for the retest and rejection and found an entry on the forth rejection where the RSI was at overbought territory. 5) we placed a stop just beyond the reach of any spikes that may occur. I hope this information will help those who don't have a clear understanding of the when, where, and how to get into a position. Taking profits is another story but I can tip you this. Measure the previous impulse and go with the 1.272 or 1.618, this all depends on where that measurement will take you...ask your self, will it test support or resistance with that measurement. Here is an example of taking profit on the 4hr timeframe. Good Luck, Cheers! Be sure to comment, follow, like, and check out my profile for more trade ideas!
NYSE:PFELong
by keifer
3
Pfizer Shizer; Do the Bears Have this One? 🏥 | PFIZER ($PFE)🧑‍⚕️ Pfizer recently announced that a clinical trial of its drug Ibrance hasn't worked out as a long-term treatment for breast cancer. This news is unfortunate on a few levels, but specifically, in terms of price, the impact isn't great. Upon releasing the news PFE dumped as analyst began to revise earnings expectations downward. This sell-off caused a reversal of the shorter term post-COVID downtrend and caused what appears to be a return to the pre-COVID downtrend. While we do think a short setup makes sense here given the facts, there is plenty of reason to be bullish from a longer-term point of view given Pfizer's projection that it could have a COVID vaccine by fall and given their funding of other COVID companies working on treatments. Resources: www.jpost.com + www.marketwatch.com + www.barrons.com ✨ Drop a comment asking for an update, we do NEW setups every day! ✨ Like, Comment & Follow to help the community grow 🎉🎉 --- 1. Fractal Trend is showing a fresh downtrend (Maroon colored bars) on the 1-hour timeframe. 2. With this strategy, we are looking for short setups in an downtrend and as such want to enter short on retests of bearish order blocks plotted by Orderblock Mapping (Maroon colored lines) and/or bearish S/R levels plotted by Directional Bias (Maroon colored lines). 3. The play here is simple, we are looking for a reaction at the R1 S/R flip and then are targeting the S1 orderblock at the current low. Then, by placing a stop just above the S/R flip, we have ourselves a solid 4.09 risk/reward ratio. 4. Other levels to the upside to watch here are R2 and R3 bearish orderblocks which should see a reaction if and when we move to the upside. 5. Below, the S2 and S3 bullish orderblocks should provide support if we move to the downside. Keep in mind we are only looking to short weakness in the near term here, as time goes on PFE should find support and potential COVID cures could easily send this stock back up. Until then, good luck bears!
NYSE:PFE
by AlphaBotSystem
1
PFE ANALYSIS, LONGER TERM, FUNDAMENTAL/TECHNICALFinancial Highlights Fiscal Year Fiscal Year Ends Dec 30, 2019 Most Recent Quarter (mrq) Mar 28, 2020 Profitability Profit Margin 31.17% Operating Margin (ttm) 29.36% Management Effectiveness Return on Assets (ttm) 5.78% Return on Equity (ttm) 25.41% Income Statement Revenue (ttm) 50.66B Revenue Per Share (ttm) 9.13 Quarterly Revenue Growth (yoy) -8.30% Gross Profit (ttm) 41.74B EBITDA 20.53B Net Income Avi to Common (ttm) 15.78B Diluted EPS (ttm) 2.80 Quarterly Earnings Growth (yoy) -12.40% Balance Sheet Total Cash (mrq) 10.36B Total Cash Per Share (mrq) 1.87 Total Debt (mrq) 52.29B Total Debt/Equity (mrq) 80.03 Current Ratio (mrq) 1.02 Book Value Per Share (mrq) 11.71 Cash Flow Statement Operating Cash Flow (ttm) 14.02B Levered Free Cash Flow (ttm) 19.44B Trading Information Stock Price History Beta (5Y Monthly) 0.71 52-Week Change 3 -9.57% S&P500 52-Week Change 3 8.60% 52 Week High 3 44.56 52 Week Low 3 27.88 50-Day Moving Average 3 37.33 200-Day Moving Average 3 36.75 Share Statistics Avg Vol (3 month) 3 30.54M Avg Vol (10 day) 3 28.54M Shares Outstanding 5 5.55B Float 5.55B % Held by Insiders 1 0.04% % Held by Institutions 1 72.56% Shares Short (May 14, 2020) 4 52.59M Short Ratio (May 14, 2020) 4 2.33 Short % of Float (May 14, 2020) 4 0.95% Short % of Shares Outstanding (May 14, 2020) 4 0.95% Shares Short (prior month Apr 14, 2020) 4 44.31M Dividends & Splits Forward Annual Dividend Rate 4 1.52 Forward Annual Dividend Yield 4 3.98% Trailing Annual Dividend Rate 3 1.46 Trailing Annual Dividend Yield 3 3.82% 5 Year Average Dividend Yield 4 3.54 Payout Ratio 4 52.14% Dividend Date 3 Jun 04, 2020 Ex-Dividend Date 4 May 06, 2020 Last Split Factor 2 3:1 Last Split Date 3 Jun 30, 1999 Key Executives Name Title Pay Exercised Year Born Dr. Albert Bourla D.V.M., DVM, Ph.D. Chairman & CEO 5.84M 2.12M 1962 Mr. John D. Young Group Pres & Chief Bus. Officer 3.36M 3.83M 1965 Mr. Frank A. D'Amelio CFO & EVP of Global Supply & Bus. Operations 3.84M 8.47M 1958 Dr. Mikael Dolsten Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical 3.66M 7.93M 1959 Ms. Jennifer B. Damico Sr. VP, Controller & Principal Accounting Officer N/A N/A 1968 I am not a financial advisor and i do not recommend you taking any of my trades. I am not responsible for any of your profits or losses. This analysis is purely for entertainment only, and it represents what could happen with the stock. Analysis like every analysis is never 100% accurate and it can easely go south because of the news we cannot control. I post this analysis only for a idea. If you would like to get funded account you can contact me. Not US residents. Rene Pungartnik blackstock
NYSE:PFE
by UnknownUnicorn7025460
1